Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May 26:13:1756284820927550.
doi: 10.1177/1756284820927550. eCollection 2020.

Complementary and alternative medications in the management of inflammatory bowel disease

Sherman Picardo  1 , Mansour Altuwaijri  1 , Shane M Devlin  1 , Cynthia H Seow  2
Affiliations
Review

Complementary and alternative medications in the management of inflammatory bowel disease

Sherman Picardo et al. Therap Adv Gastroenterol. .

Abstract

The use of complementary and alternative medications (CAM), products, and therapies not considered to be part of conventional medicine is common among patients with inflammatory bowel disease (IBD). Patients often turn to these therapies as they are considered natural and safe, with significant benefit reported beyond disease control. There is emerging evidence that some of these therapies may have anti-inflammatory activity; however, robust evidence for their efficacy in modulating disease activity is currently lacking. Patients often avoid discussing the use of CAM with their physicians, which may lead to drug interactions and/or reduced adherence with conventional therapy. It is important for physicians to be aware of the commonly used CAM and current evidence behind these therapies in order to better counsel their patients about their use in the management of IBD. This narrative review provides an overview of the evidence of the more commonly used CAM in patients with IBD.

Keywords: Crohn’s disease; aloe vera; complementary and alternative medicine; curcumin; fish oil; inflammatory bowel disease; omega 3- fatty acids; probiotics; ulcerative colitis; wormwood.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: Cynthia H. Seow has served as a consultant, speaker and has served on advisory boards for Janssen Pharmaceuticals, Abbvie, Takeda, Ferring, Shire, and Pfizer. Shane M. Devlin has served as a consultant, speaker and has served on advisory boards for Janssen Pharmaceuticals, Abbvie, Takeda, Ferring, Shire, and Pfizer. Sherman Picardo has served as a speaker for Janssen Pharmaceuticals, Abbie, Pfizer and Takeda.

Figures

Figure 1.
Figure 1.
Literature search results. CAM use in IBD. CAM, complementary and alternative medication; IBD, inflammatory bowel diseases.
See this image and copyright information in PMC

References

    1. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60: 571–607. - PubMed
    1. Liverani E. How to predict clinical relapse in inflammatory bowel disease patients. World J Gastroenterol 2016; 22: 1017–1033. - PMC - PubMed
    1. Sokol H, Seksik P, Cosnes J. Complications and surgery in the inflammatory bowel diseases biological era. Curr Opin Gastroenterol 2014; 30: 378–384. - PubMed
    1. McLean LP, Cross RK. Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. Expert Rev Gastroenterol Hepatol 2014; 8: 223–240. - PMC - PubMed
    1. Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohn’s Colitis 2010; 4: 355–366. - PubMed

LinkOut - more resources